Growth Factor News and Research

RSS

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

A high concentration of multi-strain probiotic helps to reduce mild to moderate episodes of chemotherapy-induced diarrhea in cancer patients, according to results of a phase II/III study in India.

22 Oct 2018

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

22 Oct 2018

Research provides insight into neurobiology of aggression and bullying

Duke-NUS researchers have discovered that a growth factor protein, called brain-derived neurotrophic factor, and its receptor, tropomyosin receptor kinase B affects social dominance in mice. The research has implications for understanding the neurobiology of aggression and bullying.

20 Oct 2018

Immunotherapy medicine found to be effective in treating uveitis

A team of researchers from the UCH CEU's Biomedical Sciences Institute has tested the efficiency of Bevacizumab, medicine used against cancer and in ophtalmology, to treat uveítis, thus stopping the inflammation from spreading.

19 Oct 2018

$11 million NIH grant for Clemson University helps launch new center for musculoskeletal research

With an $11 million grant from the National Institutes of Health Center for Biomedical Research Excellence, Clemson University has launched the South Carolina Center for Translational Research Improving Musculoskeletal Health, or SC-TRIMH, a new research center that will bring together scientists from across South Carolina to change the way musculoskeletal disorders are diagnosed, treated and even studied.

19 Oct 2018

Study of Nigerian breast cancer patients reveals prevalence of aggressive molecular features

A study comparing DNA and RNA data from Nigerian breast cancer patients to patients in a United States database found that certain aggressive molecular features were far more prevalent in tumors from Nigerian women than in black or white American women.

16 Oct 2018

Zebrafish study uncovers molecular 'brake' that helps control eye lens development

How different cells in a multicellular organism acquire their identities remains a fundamental mystery of development. In the eye, for example, the lens contains two cell types - lens epithelial cells and lens fiber cells -- the first of which differentiates into the second as an animal matures.

16 Oct 2018

Research points to potential new treatment for hearing loss

Researchers have taken an important step toward what may become a new approach to restore the hearing loss. In a new study, out today in the European Journal of Neuroscience, scientists have been able to regrow the sensory hair cells found in the cochlea - a part of the inner ear - that converts sound vibrations into electrical signals and can be permanently lost due to age or noise damage.

15 Oct 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

New blood test may detect early-stage lung cancer when surgical intervention is not possible

Non-small-cell lung carcinoma is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers are developing a blood test to detect lung cancer earlier in the disease.

8 Oct 2018

Study identifies camelid nanobodies capable of blocking EGF in cancer cells

The natural world often provides the answer to unsolved medical problems. On this occasion, the solution to a challenge posed by cancer has come about from the immune system of camelids.

3 Oct 2018

High levels of fibroblast growth factor 23 may affect brain health

Scientists at the Medical University of South Carolina have uncovered mechanisms by which high levels of a hormone called FGF23 can reduce brain health.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

Genervon reports new findings that drug candidate GM6 attenuates Alzheimer's disease in mice model

Following the closure of several research programs for Alzheimer's disease, in early 2018 the FDA issued a release entitled "Draft Guidance for Industry: Early Alzheimer's Disease: Developing Drugs for Treatment." Encouraged by the proposed changes in the new guidance, Genervon's research team reported new findings that its drug candidate GM6 attenuates Alzheimer's disease in an early AD transgenic APP mice model.

25 Sep 2018

Immunologist to study how Chikungunya causes devastating effects in older adults

Emerging viruses such as Ebola, SARS and swine flu are familiar sounding, yet seemingly distant diseases to many Americans. But that's not the case with Chikungunya, a mosquito-borne virus that recently struck close to home and has proven deadly for the elderly.

25 Sep 2018

Ipsen receives approval from Health Canada for CABOMETYX tablets for treating renal cell carcinoma

Exelixis, Inc. today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® tablets for the treatment of adults with advanced renal cell carcinoma who have received prior vascular endothelial growth factor targeted therapy.

19 Sep 2018